Europe
New research published in The Journal of Physiology has shed light on how to disrupt chemical signals that affect how much someone eats, which could lead to a method for helping manage obesity.
With the holiday upon us, many companies in the pharma and biotech industry have made some important announcements – some big, some small. BioSpace has gathered a number of announcements that might have gone unnoticed and put them together below.
On Tuesday, Sandoz AG, Novartis’ subsidiary focused on generic drugs and biosimilars, teamed up with Tilray Canada, Ltd., a subsidiary of Tilray Inc. to increase availability of high quality medical cannabis products across the globe.
Under the terms of the agreement, Pfizer will combine its consumer healthcare business with GSK’s existing consumer healthcare business. The combined global sales were about $12.7 billion last year. Closing is expected in the second half of 2019, dependent on GSK’s shareholder approval and regulatory approvals.
Paris-based Sanofi announced it was transferring its listing of American Depositary Shares (ADS) from the New York Stock Exchange (NYSE) to The Nasdaq Global Select Market starting end-of-day December 31, 2018. They will start trading on January 2, 2019.
Maintaining a high negative pressure in airborne infection isolation rooms of hospitals (over -10 Pa) and in renovation sites (over -5 Pa) effectively limits the dispersion of airborne contaminants and dust, a new study from the University of Eastern Finland shows.
Following the announcement of positive results from Janssen’s Phase III open label long- term extension study, which evaluates the efficacy and safety data of Stelara in Crohn’s Disease (CD),
Healthtech will rise to prominence in 2019 as Big Data and Artificial Intelligence (AI) become a transformational force in healthcare, says GlobalData, a leading data and analytics company.
For many people France may is synonymous with wines, cheese and rich meals. But the country also has a strong biotech community that how grown significantly over the past decade, with a strong focus on developing clinical drug assets.
EvaluatePharma and Vantage recently released their Vantage 2019 Preview which looks at the current year’s biopharma market and makes projections about the upcoming year.
PRESS RELEASES